Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD
Science Translational Medicine · 03.12.2025 · 17 (827)
DOI: 10.1126/scitranslmed.adv2293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 03.12.2025. Verfasst von Xinyang Yu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China. Hauptthemen laut MEDLINE: Nanoparticles, Immunotherapy, RNA, Messenger, Lipids. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Science and Technology Commission, National key R&D program of China.
Abstract (Originalsprache)
Metabolic dysfunction–associated fatty liver disease (MAFLD), a leading cause of hepatocellular carcinoma (HCC), poses a formidable therapeutic challenge because of the metabolic stress–induced aberrant immune microenvironment. However, no effective pharmacological therapies for the liver microenvironment remodeling in MAFLD are now available. Here, we developed a lipid nanoparticle (Def-LNP) that incorporates vitamin E–derived phosphatidylcholine (VEPC). Def-LNP effectively ameliorated the hepatic oxidative microenvironment to achieve sustained localized expression of target mRNA in hepatocytes in preclinical models, outperforming a commercially used LNP formulation. In vivo delivery efficiency, stability, and biosafety of Def-LNP were validated in various mammalian models, including mice, pigs, and nonhuman primates. Using clinical samples, we identified a pronounced correlation between T cell protein tyrosine phosphatase (TCPTP) and MAFLD pathogenesis. The administration of Def-LNP loaded with TCPTP-encoding mRNA (Def-LNP@mRNA TCPTP ) suppressed signal transducer and activator of transcription signaling in the hepatocytes of MAFLD mice, leading to hepatic metabolic reprogramming and immunological reconfiguration, a characteristic that is prominently lacking in conventional mRNA-based protein replacement therapy. In preclinical models, the administration of Def-LNP@mRNA TCPTP successfully eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved the therapeutic responsiveness of HCC to cancer vaccine and immune checkpoint blockade therapy. Def-LNP@mRNA TCPTP represents a potential therapeutic strategy for MAFLD and MAFLD-related HCC, potentially offering treatment paradigms for immunotherapy for HCC and metabolic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China.
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P. R. China.
- MOE Joint International Research Laboratory of Pancreatic Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P. R. China.
- Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, P. R. China.
- Department of Nuclear Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P. R. China.
- Cancer Center, Zhejiang University, Hangzhou 310003, P. R. China.
ORCID-Profile: Xinyang Yu, Shaolong Qi, Wanyue Cao, Meiqi Cheng, Meixin Lu, Qi Zhang, Guocan Yu
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission
- National key R&D program of China
- Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study
Zitieren
APA
Yu, X., Qi, S., Cao, W., Cheng, M., Zhang, W., Wang, Y., Zheng, R., Jin, G., Gao, X., Lu, M., Lei, J., Peng, K., Su, X., Zhang, Q., & Yu, G. (2025). Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD. Science Translational Medicine, 17(827). https://doi.org/10.1126/scitranslmed.adv2293
Vancouver
Yu X, Qi S, Cao W, Cheng M, Zhang W, Wang Y, et al. Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD. Science Translational Medicine. 2025;17(827). doi:10.1126/scitranslmed.adv2293
BibTeX
@article{Yu2025,
author = {Yu, Xinyang and Qi, Shaolong and Cao, Wanyue and Cheng, Meiqi and Zhang, Wenjie and Wang, Yangfan and Zheng, Rujia and Jin, Gaowei and Gao, Xiaomin and Lu, Meixin and Lei, Jiaqi and Peng, Kun and Su, Xinhui and Zhang, Qi and Yu, Guocan},
title = {Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {827},
doi = {10.1126/scitranslmed.adv2293}
}
EUVIMED